PATENT CLAIM ANALYSIS

Application Number: 15965638
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-01
Patent Classification: ["514", "125000"]

Abstract:
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Claim (Index 29):
A method for treating a subject in need thereof, comprising administering to the subject an injectable pharmaceutical emulsion, wherein the emulsion comprises:\n a neurokinase-1 (NK-1) receptor antagonist; 11 wt/wt % to 15 wt/wt % of an emulsifier; an oil; a co-surfactant which comprises an alcohol; a tonicity agent; a pH modifier; and water; wherein the pH of the emulsion ranges from about 7.5 to 9.0, and the ratio of the emulsifier to the NK-1 receptor antagonist ranges from about 18:1 to 22:1 (wt/wt %).

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.43182
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15012532', '14859013', '15398928', '15705201', '15083071']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7526288146371349
- 35 USC 102 Novelty (BERT): 0.5825768850355832
- Combined Prediction Score: 0.7356236216769797
- Mean Citation Score: 362.065834
- Max Citation Score: 465.3423
- Similarity Product: 437.08922724283934

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test